187 related articles for article (PubMed ID: 32778552)
1.
Carvalhaes CG; Duncan LR; Wang W; Sader HS
Antimicrob Agents Chemother; 2020 Oct; 64(11):. PubMed ID: 32778552
[TBL] [Abstract][Full Text] [Related]
2. Surveillance of Omadacycline Activity Tested against Clinical Isolates from the United States and Europe: Report from the SENTRY Antimicrobial Surveillance Program, 2016 to 2018.
Pfaller MA; Huband MD; Shortridge D; Flamm RK
Antimicrob Agents Chemother; 2020 Apr; 64(5):. PubMed ID: 32071045
[TBL] [Abstract][Full Text] [Related]
3. Activity of the Novel Aminomethylcycline KBP-7072 and Comparators against 1,057 Geographically Diverse Recent Clinical Isolates from the SENTRY Surveillance Program, 2019.
Huband MD; Thompson JD; Gurung ND; Liu Q; Li L; Zhang J; Streit JM; Castanheira M
Antimicrob Agents Chemother; 2022 Jan; 66(1):e0139721. PubMed ID: 34633850
[TBL] [Abstract][Full Text] [Related]
4. Activity of dalbavancin tested against Gram-positive clinical isolates causing skin and skin-structure infections in paediatric patients from US hospitals (2014-2015).
Pfaller MA; Mendes RE; Sader HS; Castanheira M; Flamm RK
J Glob Antimicrob Resist; 2017 Dec; 11():4-7. PubMed ID: 28735053
[TBL] [Abstract][Full Text] [Related]
5. Contezolid: First Approval.
Hoy SM
Drugs; 2021 Sep; 81(13):1587-1591. PubMed ID: 34365606
[TBL] [Abstract][Full Text] [Related]
6. Surveillance of tigecycline activity tested against clinical isolates from a global (North America, Europe, Latin America and Asia-Pacific) collection (2016).
Pfaller MA; Huband MD; Streit JM; Flamm RK; Sader HS
Int J Antimicrob Agents; 2018 Jun; 51(6):848-853. PubMed ID: 29410368
[TBL] [Abstract][Full Text] [Related]
7. Surveillance of omadacycline activity tested against clinical isolates from the United States and Europe: Results from the SENTRY Antimicrobial Surveillance Programme, 2017.
Huband MD; Pfaller MA; Shortridge D; Flamm RK
J Glob Antimicrob Resist; 2019 Dec; 19():56-63. PubMed ID: 30825698
[TBL] [Abstract][Full Text] [Related]
8. Ceftobiprole Activity against Bacteria from Skin and Skin Structure Infections in the United States from 2016 through 2018.
Flamm RK; Duncan LR; Hamed KA; Smart JI; Mendes RE; Pfaller MA
Antimicrob Agents Chemother; 2020 May; 64(6):. PubMed ID: 32179519
[TBL] [Abstract][Full Text] [Related]
9. Contezolid in complicated skin and soft tissue infection.
Kaul G; Dasgupta A; Chopra S
Drugs Today (Barc); 2022 Jul; 58(7):315-326. PubMed ID: 35851867
[TBL] [Abstract][Full Text] [Related]
10.
Wang S; Cai C; Shen Y; Sun C; Shi Q; Wu N; Zheng S; Qian J; Zhang R; Zhou H
Front Microbiol; 2021; 12():729900. PubMed ID: 34489919
[TBL] [Abstract][Full Text] [Related]
11. Antimicrobial activity of ceftobiprole, a novel anti-methicillin-resistant Staphylococcus aureus cephalosporin, tested against contemporary pathogens: results from the SENTRY Antimicrobial Surveillance Program (2005-2006).
Fritsche TR; Sader HS; Jones RN
Diagn Microbiol Infect Dis; 2008 May; 61(1):86-95. PubMed ID: 18385000
[TBL] [Abstract][Full Text] [Related]
12. Tolerability and Pharmacokinetics of Contezolid at Therapeutic and Supratherapeutic Doses in Healthy Chinese Subjects, and Assessment of Contezolid Dosing Regimens Based on Pharmacokinetic/Pharmacodynamic Analysis.
Wu J; Wu H; Wang Y; Chen Y; Guo B; Cao G; Wu X; Yu J; Wu J; Zhu D; Guo Y; Yuan H; Hu F; Zhang J
Clin Ther; 2019 Jun; 41(6):1164-1174.e4. PubMed ID: 31126694
[TBL] [Abstract][Full Text] [Related]
13. A Novel Oxazolidinone, Contezolid (MRX-I), Expresses Anti-Mycobacterium abscessus Activity
Guo Q; Xu L; Tan F; Zhang Y; Fan J; Wang X; Zhang Z; Li B; Chu H
Antimicrob Agents Chemother; 2021 Oct; 65(11):e0088921. PubMed ID: 34460305
[TBL] [Abstract][Full Text] [Related]
14. Activity of tedizolid against gram-positive clinical isolates causing infections in Europe and surrounding areas (2014-2015).
Pfaller MA; Sader HS; Shortridge D; Castanheira M; Flamm RK; Mendes RE
J Chemother; 2019 Jul; 31(4):188-194. PubMed ID: 31079589
[TBL] [Abstract][Full Text] [Related]
15. Zyvox Annual Appraisal of Potency and Spectrum program: linezolid surveillance program results for 2008.
Jones RN; Ross JE; Bell JM; Utsuki U; Fumiaki I; Kobayashi I; Turnidge JD
Diagn Microbiol Infect Dis; 2009 Dec; 65(4):404-13. PubMed ID: 19913683
[TBL] [Abstract][Full Text] [Related]
16. Telavancin activity in vitro tested against a worldwide collection of Gram-positive clinical isolates (2014).
Duncan LR; Sader HS; Smart JI; Flamm RK; Mendes RE
J Glob Antimicrob Resist; 2017 Sep; 10():271-276. PubMed ID: 28735051
[TBL] [Abstract][Full Text] [Related]
17. Surveillance of Omadacycline Activity Tested against Clinical Isolates from the United States and Europe as Part of the 2016 SENTRY Antimicrobial Surveillance Program.
Pfaller MA; Huband MD; Shortridge D; Flamm RK
Antimicrob Agents Chemother; 2018 Apr; 62(4):. PubMed ID: 29378719
[TBL] [Abstract][Full Text] [Related]
18. Population Pharmacokinetics Study of Contezolid (MRX-I), a Novel Oxazolidinone Antibacterial Agent, in Chinese Patients.
Li L; Wu H; Chen Y; Yuan H; Wu J; Wu X; Zhang Y; Cao G; Guo B; Wu J; Zhao M; Zhang J
Clin Ther; 2020 May; 42(5):818-829. PubMed ID: 32389326
[TBL] [Abstract][Full Text] [Related]
19. Setting of the tentative epidemiological cut-off values of contezolid for Staphylococcus aureus, Enterococcus faecalis, Enterococcus faecium, Streptococcus pneumoniae and Streptococcus agalactiae.
Guo Y; Han R; Zhang G; Yang Q; Xue F; Li Y; Zhu D; Hu F
J Antimicrob Chemother; 2023 Apr; 78(4):1055-1058. PubMed ID: 36849586
[TBL] [Abstract][Full Text] [Related]
20. In Vitro Activities of LCB 01-0648, a Novel Oxazolidinone, against Gram-Positive Bacteria.
Oh SH; Kim J; Baek SY; Chae SE; Park HS; Cho YL; Kwak JH
Molecules; 2017 Mar; 22(3):. PubMed ID: 28273820
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
